PURPOSE: Mismatch repair genes are responsible for the coordinated correction of misincorporated nucleotides formed during DNA replication. Inactivating and inherited mutations in the prototypic mismatch repair gene hMSH2 have been described in a cancer predisposition syndrome known as hereditary nonpolyposis colon cancer. Patients with hereditary nonpolyposis colon cancer are at increased risk for colon cancer and extracolonic cancers such as upper tract transitional cell carcinoma but not prostate cancer. We investigated expression of hMSH2 in prostate cancer cell lines using genetic and molecular analysis. MATERIALS AND METHODS: We used the 3 well described prostate cancer cell lines, DU145, LNCaP and PC3. Western blot analysis with monoclonal antibody to hMSH2 was used to assess expression. Southern blot and polymerase chain reaction of genomic DNA were used to identify genetic alterations in the hMSH2 gene. Single cell cloning, dinucleotide repeats and BAT-26 were used to assess the cell lines for microsatellite instability. RESULTS: The prostate cancer cell line LNCaP did not express hMSH2 and was found to have a homozygous deletion of hMSH2 exons 9 to 16, resulting in truncation of the protein. While microsatellite analysis did not reveal alterations at the BAT-26 locus, single cell cloning produced several LNCaP subclones with alteration at 1 dinucleotide repeat. CONCLUSIONS: The well described prostate cancer cell line LNCaP has a mutation in the hMSH2 gene, resulting in loss of expression and possible evidence of microsatellite instability. To our knowledge our finding is the first demonstration of a genetic alteration in hMSH2 in a prostate cancer cell line.
PURPOSE: Mismatch repair genes are responsible for the coordinated correction of misincorporated nucleotides formed during DNA replication. Inactivating and inherited mutations in the prototypic mismatch repair gene hMSH2 have been described in a cancer predisposition syndrome known as hereditary nonpolyposis colon cancer. Patients with hereditary nonpolyposis colon cancer are at increased risk for colon cancer and extracolonic cancers such as upper tract transitional cell carcinoma but not prostate cancer. We investigated expression of hMSH2 in prostate cancer cell lines using genetic and molecular analysis. MATERIALS AND METHODS: We used the 3 well described prostate cancer cell lines, DU145, LNCaP and PC3. Western blot analysis with monoclonal antibody to hMSH2 was used to assess expression. Southern blot and polymerase chain reaction of genomic DNA were used to identify genetic alterations in the hMSH2 gene. Single cell cloning, dinucleotide repeats and BAT-26 were used to assess the cell lines for microsatellite instability. RESULTS: The prostate cancer cell line LNCaP did not express hMSH2 and was found to have a homozygous deletion of hMSH2 exons 9 to 16, resulting in truncation of the protein. While microsatellite analysis did not reveal alterations at the BAT-26 locus, single cell cloning produced several LNCaP subclones with alteration at 1 dinucleotide repeat. CONCLUSIONS: The well described prostate cancer cell line LNCaP has a mutation in the hMSH2 gene, resulting in loss of expression and possible evidence of microsatellite instability. To our knowledge our finding is the first demonstration of a genetic alteration in hMSH2 in a prostate cancer cell line.
Authors: Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan Journal: Clin Cancer Res Date: 2017-08-08 Impact factor: 12.531
Authors: Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Belinda Nghiem; Xiaotun Zhang; Hung-Ming Lam; Lawrence D True; Ilsa Coleman; Celestia S Higano; Peter S Nelson; Colin C Pritchard; Colm Morrissey Journal: Asian J Urol Date: 2016-09-12
Authors: Inês Teles Alves; David Cano; René Böttcher; Hetty van der Korput; Winand Dinjens; Guido Jenster; Jan Trapman Journal: Oncotarget Date: 2017-01-24
Authors: Lien Spans; Christine Helsen; Liesbeth Clinckemalie; Thomas Van den Broeck; Stefan Prekovic; Steven Joniau; Evelyne Lerut; Frank Claessens Journal: PLoS One Date: 2014-02-28 Impact factor: 3.240
Authors: Yezi Zhu; Susan L Dalrymple; Ilsa Coleman; S Lilly Zheng; Jianfeng Xu; Jody E Hooper; Emmanuel S Antonarakis; Angelo M De Marzo; Alan K Meeker; Peter S Nelson; William B Isaacs; Samuel R Denmeade; Jun Luo; W Nathaniel Brennen; John T Isaacs Journal: Oncogene Date: 2020-09-28 Impact factor: 9.867